English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Mologen Licenses the China Rights of its Lead Compound, Lefitolimod, to Oncologie with Expected Milestone Payments Exceeding 100 million Euros

Feb. 13, 2018

Germany-based Mologen has signed a license deal for the Chinese territory and a global co-development agreement with Oncologie for its lead compound lefitolimod. Oncologie is an oncology-focused drug development company with headquarters in Boston and operations in Shanghai. Mologen is to receive a EUR 3 million initial payment; a EUR 2 million equity investment, development milestone payments of over EUR 100 million, as well as double digit royalties on net sales.